In a research report released today, H.C.
Maxim Group analyst Jason Kolbert reiterated a Buy rating on Vertex Pharmaceuticals (NASDAQ:VRTX) and raised his share price target to $122 (from $117), …
In a research report issued to investors Wednesday, Oppenheimer analyst Yigal Nochomovitz reiterated a Perform rating on Vertex Pharmaceuticals (NASDAQ:VRTX), following the company’s third-quarter …
In a research report issued today, H.C.
In a report sent to investors today, Oppenheimer analyst Yigal Nochomovitz maintained a Perform rating on Vertex Pharmaceuticals (NASDAQ:VRTX), following the positive FDA advisory panel …
In a research report issued today, Oppenheimer analyst Yigal Nochomovitz maintained a Perform rating on Vertex Pharmaceuticals (NASDAQ:VRTX), while no price target was provided. Nochomovitz …
In a research report issued yesterday, Janney Capital Markets analyst Kimberly Lee reiterated a Buy rating on Vertex Pharmaceuticals Inc. (VRTX) and gave it a Fair Value Estimate …
In a research note released today, H.C.
In a research report published today, Janney Capital analyst Kimberly Lee maintained a Buy rating on Vertex Pharmaceuticals (VRTX) with a $110 price …
